A Study of E7080 in Subjects With Advanced Thyroid Cancer
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety, efficacy, and pharmacokinetics of E7080 when orally
administered once daily (QD) in subjects with advanced thyroid cancer.